What is GRAL's market cap?

$6.42B, based on the Nov 4 close of $143.66.

Does GRAIL pay a dividend?

No regular cash dividend has been paid in the last year.

How much of GRAL is sold short?

8.2M shares, 19.3% of float, as of Oct 15, 2026.

What sector is GRAL in?

Healthcare, in the Medical Labs industry.

NASDAQ · GRALHealthcareMedical Labs

GRAIL, Inc. Common Stock (GRAL)

$143.66+3.03%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$143.66▲ 78.04% in range

Nov 4, 2025Low $43.03 · High $158.92Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

GRAIL closed at $143.66 on Nov 4, up 3.03%, 9.6% below its 52-week closing high. Volume of 761.1K shares was 0.82× its 20-day average (close to normal).

Split-adjusted performance: +4.6% over one month, +128.9% over six months.

In the quarter ended Jun 30, 2026, revenue was $44.69M, up 25.7% from a year earlier, with a net margin of -246.7%.

Short interest was 8.2M shares at the Oct 15 settlement, up 2.1% from the prior report (19.3% of float, 8.0 days to cover).

Market cap$6.42B44.7M shares

Revenue · quarter$44.7M+25.7% YoY

Diluted EPS$-2.56—

P/E · TTM—P/S 38.8×

Net margin-246.7%Gross -28.1%

Dividend yieldNone

52-week range43.03 – 158.92−9.6% from high

Volume761.1K0.82× 20-day avg

Volatility · 60d96.8%Annualised

Short % of float19.3%8.0 days to cover

Net cash$861.6MCash $861.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −9.0%1M +4.6%3M +126.6%6M +128.9%YTD +67.8%1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum86

Revenue growth56

Net margin14

Value (low P/E)—

Size78

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →

Shares short8.2M+2.1% vs prior

Days to cover8.0Settled Oct 15

% of float19.3%

Short vol. 10d60.8%of daily volume

Closest peers by size in Medical Labs

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
GRALGRAIL	$143.66	+3.03%	+128.9%	+25.7%	−246.7%	—	$6.42B
RDNTRadNet	$80.26	+9.67%	+36.9%	+25.0%	1.2%	—	$6.32B	Compare
BLLNBillionToOne	$113.89	+3.11%	+39.9%	—	7.4%	—	$5.37B	Compare
CDNACareDx	$85.86	−2.95%	+309.8%	+39.3%	13.8%	35.1	$4.51B	Compare
CAICaris Life Sciences	$33.22	+1.13%	+73.7%	+45.4%	−0.2%	89.3	$9.39B	Compare
VCYTVeracyte	$52.52	+4.43%	+27.5%	+15.5%	17.0%	36.9	$4.22B	Compare
CELCCelcuity	$69.24	−0.69%	−50.3%	—	—	—	$3.39B	Compare
FTREFortrea Holdings	$20.83	−0.57%	+33.2%	−1.4%	0.1%	—	$2.01B	Compare
GHGuardant Health	$168.58	−3.67%	+82.7%	+44.3%	−35.9%	—	$22.62B	Compare

News about GRAIL

All news →

Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore.The Motley Fool · Oct 11, 2026Neutral 3 Reasons to Buy Grail (GRAL) Hand Over Fist in OctoberThe Motley Fool · Sep 30, 2026▲ Positive GRAL FINAL DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff DeadlineGlobeNewswire Inc. · Aug 3, 2026▼ Negative Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?The Motley Fool · Aug 1, 2026▲ Positive GRAL DEADLINE TUESDAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRALGlobeNewswire Inc. · Aug 1, 2026▼ Negative

Quick answers

What does GRAIL do?: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
What is GRAL's market cap?: $6.42B, based on the Nov 4 close of $143.66.
Does GRAIL pay a dividend?: No regular cash dividend has been paid in the last year.
How much of GRAL is sold short?: 8.2M shares, 19.3% of float, as of Oct 15, 2026.
What sector is GRAL in?: Healthcare, in the Medical Labs industry.

About GRAIL

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

HQ: Menlo Park, CA910 employeesListed Jun 12, 2024grail.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology